128 related articles for article (PubMed ID: 29029123)
21. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
22. Serum CA125 level before the development of ovarian cancer.
Kobayashi H; Ooi H; Yamada Y; Sakata M; Kawaguchi R; Kanayama S; Sumimoto K; Terao T
Int J Gynaecol Obstet; 2007 Nov; 99(2):95-9. PubMed ID: 17643440
[TBL] [Abstract][Full Text] [Related]
23. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
[TBL] [Abstract][Full Text] [Related]
24. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
[TBL] [Abstract][Full Text] [Related]
26. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
27. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records.
Funston G; Mounce LT; Price S; Rous B; Crosbie EJ; Hamilton W; Walter FM
Br J Gen Pract; 2021 Jun; 71(707):e465-e472. PubMed ID: 33875416
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
29. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
31. CA125 response: can it replace the traditional response criteria in ovarian cancer?
Guppy AE; Rustin GJ
Oncologist; 2002; 7(5):437-43. PubMed ID: 12401906
[TBL] [Abstract][Full Text] [Related]
32. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
Ikeda Y; Hasegawa K; Kurosaki A; Miyara A; Hanaoka T; Shintani D; Imai Y; Nishikawa T; Oda K; Fujiwara K
Oncol Res Treat; 2015; 38(6):276-81. PubMed ID: 26045023
[TBL] [Abstract][Full Text] [Related]
33. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
34. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
Uehara T; Yoshida H; Fukuhara M; Yoshida M; Motoi N; Sugawara S; Sone M; Arai Y; Tamura K; Uno M; Ishikawa M; Kato T
Gynecol Oncol; 2020 May; 157(2):398-404. PubMed ID: 32063274
[TBL] [Abstract][Full Text] [Related]
37. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
[TBL] [Abstract][Full Text] [Related]
38. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.
Sturgeon CM; Duffy MJ; Walker G
Ann Clin Biochem; 2011 Jul; 48(Pt 4):295-9. PubMed ID: 21746796
[TBL] [Abstract][Full Text] [Related]
39. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
[TBL] [Abstract][Full Text] [Related]
40. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
